[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:cftr-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"CFTR Gene",25,19,[8,16,23,29,36,42,48,54,61,67,73,79,85,91,97,103,109,115,121,127,134,141,148,154,160],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05504837","A Study Assessing KB407 for the Treatment of Cystic Fibrosis",[12],"Phase 1","RECRUITING","2026-08-26T02:18:58.958025Z","2026-07-05T05:32:16.803851Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06429176","Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients With Cystic Fibrosis",[20],"Phase 2","2026-08-26T02:17:57.997171Z","2026-07-05T05:32:16.753730Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06654752","Streamlined Treatment of Pulmonary Exacerbations in Pediatrics",[],"2026-08-26T02:15:43.339060Z","2026-05-05T02:43:28.881471Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT03587961","Personalized Theratyping Trial",[33],"Early Phase 1","2026-08-26T02:17:44.240289Z","2026-05-05T02:43:28.839209Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT06237335","A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF",[20],"2026-08-03T03:27:47.777467Z","2026-05-05T02:43:28.540558Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT04580368","Testing Drug Efficacy in Cystic Fibrosis Through N-of-1 Trials",[],"2026-08-26T02:18:08.005333Z","2026-05-05T02:43:27.993194Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":27,"content_modified":53},"NCT05517655","BEGIN Novel ImagiNG Biomarkers",[52],"Phase 4","2026-05-05T02:43:28.849403Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":59,"content_modified":60},"NCT02000089","The Cancer of the Pancreas Screening-5 CAPS5)Study",[58],"Phase 3","2026-08-26T02:17:20.511551Z","2026-05-05T02:43:27.641158Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT03161808","Rare CFTR Mutation Cell Collection Protocol (RARE)",[],"2026-08-26T02:17:22.153941Z","2026-07-05T05:32:16.769658Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT06837181","Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)",[],"2026-08-26T02:15:23.202838Z","2026-05-13T02:55:06.584092Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT06847256","Genetic Risk Factor for Heat Stroke",[],"2026-08-26T02:16:08.402952Z","2026-05-13T02:55:06.583445Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT05474430","Estimating Risk of Respiratory Infections Attributable to CFTR Heterozygosity",[],"2026-08-26T02:16:40.941792Z","2026-05-13T02:55:06.349692Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT04793867","Regional Phenotyping of CF and Non-CF Bronchiectasis",[],"2026-08-26T02:15:10.362237Z","2026-05-13T02:55:06.270042Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT04509050","Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children",[],"2026-08-26T02:18:18.766496Z","2026-05-13T02:55:06.252325Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT06191640","Sinus Disease in Young Children With Cystic Fibrosis",[],"2026-08-26T02:18:57.189473Z","2026-05-13T02:55:06.427012Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT05474417","The Effects of the CF Carrier State on the Kidneys and Pancreas",[],"2026-08-26T02:17:03.534765Z","2026-05-13T02:55:06.351832Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT01776398","Collection of Airway, Blood and\u002For Urine Specimens From Subjects for Research Studies",[],"2026-08-26T02:17:30.961790Z","2026-05-13T02:55:06.079817Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT00001532","Role of Genetic Factors in the Development of Lung Disease",[],"2026-08-26T02:18:11.042248Z","2026-05-13T02:55:06.028695Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT05359991","Exercise in Child Health",[],"2026-08-26T02:16:21.385056Z","2026-05-05T02:43:29.714592Z",{"nct_id":128,"title":129,"phases":130,"status":131,"updated_at":132,"content_modified":133},"NCT07102043","Glucose Metabolism in Cystic Fibrosis Related Diabetes (CFRD)",[],"ENROLLING_BY_INVITATION","2026-08-26T02:19:25.538428Z","2026-07-05T05:32:16.733186Z",{"nct_id":135,"title":136,"phases":137,"status":138,"updated_at":139,"content_modified":140},"NCT06154447","Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T02:22:29.706078Z","2026-05-05T02:43:29.734517Z",{"nct_id":142,"title":143,"phases":144,"status":138,"updated_at":146,"content_modified":147},"NCT05668741","A Phase 1\u002F2 Study of VX-522 in Participants With Cystic Fibrosis (CF)",[145],"Phase 1\u002FPhase 2","2026-08-03T02:17:43.428438Z","2026-05-05T02:43:29.696475Z",{"nct_id":149,"title":150,"phases":151,"status":138,"updated_at":152,"content_modified":153},"NCT07108153","Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta",[20],"2026-08-03T03:23:02.910057Z","2026-05-05T02:43:28.403527Z",{"nct_id":155,"title":156,"phases":157,"status":138,"updated_at":158,"content_modified":159},"NCT05422222","Evaluation of VX-121\u002FTezacaftor\u002FDeutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age",[58],"2026-08-03T03:02:32.170340Z","2026-05-05T02:43:27.632171Z",{"nct_id":161,"title":162,"phases":163,"status":164,"updated_at":165,"content_modified":166},"NCT06350149","A Pilot and Feasibility Study to Evaluate High vs Low Glycemic Index Mixed Meal Tolerance Test in Adolescents and Young Adults With Cystic Fibrosis",[],"UNKNOWN","2026-08-03T03:21:44.652451Z","2026-05-05T02:43:28.883953Z"]